IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: A combined result of hepatic function biomarkers and histological analysis attested that OSO, mainly OSO2%, restored the CML-impaired hepatic damage and equilibrated IL-6 and ROS generation.